Literature DB >> 25012163

HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.

Günther Silbernagel1, Bernd Genser2, Christiane Drechsler3, Hubert Scharnagl4, Tanja B Grammer5, Tatjana Stojakovic4, Vera Krane3, Eberhard Ritz6, Christoph Wanner3, Winfried März7.   

Abstract

High concentrations of HDL cholesterol are considered to indicate efficient reverse cholesterol transport and to protect from atherosclerosis. However, HDL has been suggested to be dysfunctional in ESRD. Hence, our main objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis patients with diabetes. Moreover, we investigated the associations between the major protein components of HDL (apoA1, apoA2, and apoC3) and end points. We performed an exploratory, post hoc analysis with 1255 participants (677 men and 578 women) of the German Diabetes Dialysis study. The mean age was 66.3 years and the mean body mass index was 28.0 kg/m(2). The primary end point was a composite of cardiac death, myocardial infarction, and stroke. The secondary end point included all-cause mortality. The mean duration of follow-up was 3.9 years. A total of 31.3% of the study participants reached the primary end point and 49.1% died from any cause. HDL cholesterol and apoA1 and apoC3 quartiles were not related to end points. However, there was a trend toward an inverse association between apoA2 and all-cause mortality. The hazard ratio for death from any cause in the fourth quartile compared with the first quartile of apoA2 was 0.63 (95% confidence interval, 0.40 to 0.89). The lack of an association between HDL cholesterol and cardiovascular risk may support the concept of dysfunctional HDL in hemodialysis. The possible beneficial effect of apoA2 on survival requires confirmation in future studies.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  cardiovascular disease; chronic dialysis; lipids; mortality risk

Mesh:

Substances:

Year:  2014        PMID: 25012163      PMCID: PMC4310646          DOI: 10.1681/ASN.2013080816

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  27 in total

1.  Apolipoprotein A-II Is a negative risk indicator for cardiovascular and total mortality: findings from the Ludwigshafen Risk and Cardiovascular Health Study.

Authors:  Karl Winkler; Michael M Hoffmann; Ursula Seelhorst; Britta Wellnitz; Bernhard O Boehm; Bernhard R Winkelmann; Winfried März; Hubert Scharnagl
Journal:  Clin Chem       Date:  2008-08       Impact factor: 8.327

2.  Uremia alters HDL composition and function.

Authors:  Michael Holzer; Ruth Birner-Gruenberger; Tatjana Stojakovic; Dalia El-Gamal; Veronika Binder; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2011-07-29       Impact factor: 10.121

3.  Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.

Authors:  Suguru Yamamoto; Patricia G Yancey; T Alp Ikizler; W Gray Jerome; Ryohei Kaseda; Brian Cox; Aihua Bian; Ayumi Shintani; Agnes B Fogo; Macrae F Linton; Sergio Fazio; Valentina Kon
Journal:  J Am Coll Cardiol       Date:  2012-11-07       Impact factor: 24.094

4.  Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients.

Authors:  M Koch; B Kutkuhn; E Trenkwalder; D Bach; B Grabensee; H Dieplinger; F Kronenberg
Journal:  J Am Soc Nephrol       Date:  1997-12       Impact factor: 10.121

Review 5.  Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.

Authors:  Dick C Chan; Theodore W K Ng; Gerald F Watts
Journal:  Ann Med       Date:  2011-04-18       Impact factor: 4.709

6.  Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling.

Authors:  Meliana Riwanto; Lucia Rohrer; Bernd Roschitzki; Christian Besler; Pavani Mocharla; Maja Mueller; Damir Perisa; Kathrin Heinrich; Lukas Altwegg; Arnold von Eckardstein; Thomas F Lüscher; Ulf Landmesser
Journal:  Circulation       Date:  2013-01-24       Impact factor: 29.690

7.  Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1.

Authors:  Tomio Umemoto; Chang Yeop Han; Poulami Mitra; Michelle M Averill; Chongren Tang; Leela Goodspeed; Mohamed Omer; Savitha Subramanian; Shari Wang; Laura J Den Hartigh; Hao Wei; Eung Ju Kim; Jinkyu Kim; Kevin D O'Brien; Alan Chait
Journal:  Circ Res       Date:  2013-03-15       Impact factor: 17.367

Review 8.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Authors:  M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts
Journal:  Eur Heart J       Date:  2011-04-29       Impact factor: 29.983

Review 9.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

10.  Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

Authors:  Majken K Jensen; Eric B Rimm; Jeremy D Furtado; Frank M Sacks
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

View more
  21 in total

1.  Apoprotein B/Apoprotein A-1 Ratio and Mortality among Prevalent Dialysis Patients.

Authors:  Yuji Sato; Shouichi Fujimoto; Tatsunori Toida; Hideto Nakagawa; Yasuhiro Yamashita; Takashi Iwakiri; Akihiro Fukuda; Shuji Iwatsubo
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-15       Impact factor: 8.237

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  Risk factors: HDL-cholesterol levels and mortality in patients with ESRD.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

4.  Dialysis Modalities and HDL Composition and Function.

Authors:  Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2015-03-05       Impact factor: 10.121

Review 5.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

6.  Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.

Authors:  Chantal Kopecky; Bernd Genser; Christiane Drechsler; Vera Krane; Christopher C Kaltenecker; Markus Hengstschläger; Winfried März; Christoph Wanner; Marcus D Säemann; Thomas Weichhart
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-25       Impact factor: 8.237

Review 7.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

8.  HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

Authors:  Chantal Kopecky; Sanam Ebtehaj; Bernd Genser; Christiane Drechsler; Vera Krane; Marlies Antlanger; Johannes J Kovarik; Christopher C Kaltenecker; Mojtaba Parvizi; Christoph Wanner; Thomas Weichhart; Marcus D Säemann; Uwe J F Tietge
Journal:  J Am Soc Nephrol       Date:  2016-09-09       Impact factor: 10.121

Review 9.  Kidney as modulator and target of "good/bad" HDL.

Authors:  Jianyong Zhong; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

10.  Triglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular outcomes in prevalent dialysis patients.

Authors:  Hung-Yuan Chen; Wan-Chuan Tsai; Yen-Ling Chiu; Shih-Ping Hsu; Mei-Fen Pai; Ju-Yeh Yang; Yu-Sen Peng
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.